ICTS To Provide Study Information Websites
Raleigh, NC – Tom Sturgis, President of Integrated Clinical Trial Services (ICTS) announced that the firm has introduced a new service to provide Study Information Websites as part of a comprehensive patient services program. The Study Information Websites are third party verifiable information resources for individual clinical trials, permitting patients to look up specific information about the trial they are participating in and serving as a backup for other information sources. The Study Information Websites are web-optimized, and appear credible in the top 10 results of any search engine, resulting in additional patient recruitment as individuals search the web for information on their condition.
"We are pleased to be able to offer this new service as part of our comprehensive plan," said Sturgis. "It is important that patients have correct and valid information about their condition and can learn about opportunities to participate in clinical trials. We are excited to provide them with an additional source of knowledge."
About Integrated Clinical Trial Services:
Integrated Clinical Trial Services is a full service patient enrollment firm that provides clinical trial sponsors, contract research organizations and site networks with a comprehensive resource for patient recruitment expertise. The firm's services include patient enrollment feasibility, recruitment strategy, consulting, market research and protocol review, project management, concept design and production, media placement, community resource support, compliance and retention, and more. For more information please call (919) 388-3964. Integrated Clinical Trial Services can be found on the Internet at http://www.integratedtrials.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.